The oral DOAC, rivaroxaban, is a better alternative to subcutaneous enoxaparin for preventing VTE in immobilised patients after non-major orthopaedic surgery, a major study has shown. In a multinational European study that recruited 3,604 patients at moderate VTE risk after lower limb surgery, treatment with rivaroxaban was associated with a 75% reduction in risk of ...
Rivaroxaban better than enoxaparin for thromboprophylaxis after non-major surgery
By Michael Woodhead
30 Mar 2020